Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
Astria Therapeutics (NASDAQ: ATXS) will present two posters at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain, on June 1, 2024.
Dr. Marcus Maurer will present the ALPHA-SOLAR trial of STAR-0215 for treating hereditary angioedema (HAE), detailing its rationale and design.
Dr. Nikos Biris will present on the characterization of STAR-0310, a novel OX40 antagonistic monoclonal antibody.
Both sessions will take place on June 1 at 12:00pm CEST.
- Astria Therapeutics is actively participating in a major international conference, enhancing its visibility and credibility.
- The presentation of the ALPHA-SOLAR trial highlights ongoing research and potential future treatments for HAE, which may impact future revenues positively.
- Introducing STAR-0310, a novel monoclonal antibody, indicates pipeline diversification and innovation.
- Having reputable experts like Dr. Marcus Maurer and Dr. Nikos Biris present the data adds to the company's scientific credibility.
- No immediate financial impacts or revenue gains are mentioned, making the short-term business implications unclear.
- The effectiveness and safety of STAR-0215 and STAR-0310 remain to be proven in broader clinical settings.
- The announcement does not include any new clinical data or results, which may disappoint investors looking for immediate, actionable updates.
-
Dr. Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité Universitätsmedizin in
Berlin , will present information on ALPHA-SOLAR, a long-term open-label trial of STAR-0215 in people living with HAE, in a poster titled “Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE).” The poster session will take place on Saturday, June 1 at 12:00pm CEST. - Nikos Biris, Ph.D., Senior Director of Assay Development at Astria Therapeutics, will present information on the characterization of STAR-0310 in a poster titled “Development and Characterization of STAR-0310: a Novel OX40 Antagonistic Monoclonal Antibody.” The poster session will take place on Saturday, June 1 at 12:00pm CEST.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523463861/en/
Astria Contact:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com
Source: Astria Therapeutics, Inc.
FAQ
What will Astria Therapeutics present at the EAACI Congress 2024?
When is Astria Therapeutics presenting at the EAACI Congress 2024?
Who will present the ALPHA-SOLAR trial at the EAACI Congress?
What is the focus of the ALPHA-SOLAR clinical trial?
What is STAR-0310, and who will present about it at the EAACI Congress?
